Novartis Acquires Vedere Bio
September 30, 2020
Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.
- Buyers
- Novartis
- Targets
- Vedere Bio, Inc.
- Sellers
- Shareholders of Vedere Bio
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Astellas Acquires IVERIC bio for Approximately $5.9 Billion
April 29, 2023
Biotechnology
Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.
-
Eli Lilly Acquires Verve Therapeutics
July 25, 2025
Biotechnology
Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.
-
Novartis Acquires Gyroscope Therapeutics
December 22, 2021
Biotechnology
Novartis has agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront with up to $700 million in contingent milestone payments, adding GT005 — an AAV2-based, one-time investigational gene therapy for geographic atrophy secondary to AMD — and early-stage retinal assets to its ophthalmology pipeline. The transaction is subject to customary closing conditions and regulatory approvals; Gyroscope will continue to operate independently until closing.
-
Charles River Laboratories Acquires Vigene Biosciences
May 17, 2021
Biotechnology
Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.
-
Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)
October 26, 2020
Biotechnology
Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.